-
Mashup Score: 0Lenvatinib Maintains Status as Second-Line Therapy for Patients With HCC | Docwire News - 5 month(s) ago
The study evaluated clinical outcomes associated with lenvatinib after immunotherapy treatment.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Lenvatinib Maintains Status as Second-Line Therapy for Patients With HCC | Docwire News - 5 month(s) ago
The study evaluated clinical outcomes associated with lenvatinib after immunotherapy treatment.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
A recent study has concluded that #lenvatinib after immunotherapy progression can be beneficial as a second-line therapy for patients with hepatocellular carcinoma. Read more: https://t.co/dVTINT0DoQ https://t.co/PLXxo1v3FS
-
-
Mashup Score: 2Frontline Use of Pembrolizumab With Lenvatinib Supported in nccRCC - 8 month(s) ago
As the first study of its kind, KEYNOTE-B61 has demonstrated potential to move pembrolizumab plus lenvatinib earlier in the treatment of non-clear cell renal cell carcinoma.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Pembrolizumab given in combination with #lenvatinib has demonstrated durable antitumor efficacy in patients with non-clear cell renal cell carcinoma in the KEYNOTE-B61 study. #kcsm | @AlbigesL @GustaveRoussy https://t.co/r7na4nJaA5
-
-
Mashup Score: 0Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab - 8 month(s) ago
The incidence of uterine cancer and its associated mortality rate are increasing. This article reports key adverse reactions in patients with advanced endometri
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This report reviewed AEs from combination #lenvatinib + #pembrolizumab in patients with advanced #endometrialcancer (Study-309/KEYNOTE-775). Useful strategies: education, preventative measures/close monitoring, and dose modifications. #gyncsm @dchimd https://t.co/9lds7leVn8 https://t.co/XbV7D1ix5E
-
-
Mashup Score: 0Pembrolizumab Plus Lenvatinib Breakthroughs: KEYNOTE-581 Trial - 9 month(s) ago
Pembrolizumab plus Lenvatinib, individually known for their robust anti-cancer mechanisms, when combined, show significant promise in treating advanced renal cell carcinoma. The KEYNOTE-581 trial revealed significant improvements in survival outcomes with pembrolizumab/lenvatinib, demonstrating its potential as a …
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Exciting breakthrough in #cancertreatment! #Pembrolizuma and #lenvatinib combo shows promise for advanced renal #cellcarcinoma. Discover the potential survival benefit for patients in our in-depth article with an interview by Corina Dutcus, #ASCO23. https://t.co/UFzNnsCDZm
-
-
Mashup Score: 0Drs. Lee, McKay on KEYNOTE-B61 for Non-Clear Cell RCC | GU Oncology Now - 10 month(s) ago
Drs. Lee and McKay discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for non-clear cell renal cell carcinoma.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
At @ASCO23, @DrRanaMcKay met with @ChungHanLee3 to discuss the latest data on KEYNOTE-B61 for first-line #lenvatinib plus pembrolizumab for non-clear cell renal cell carcinoma. Watch now: https://t.co/awjZeCxkRb https://t.co/JZuqgXpUUx
-
-
Mashup Score: 0
1. Overall survival is longer for patients receiving a combination of lenvatinib plus pembrolizumab as compared with chemotherapy treatment alone 2. Progression-free survival was greater in the group receiving combination therapy Evidence Rating Level: 1 (Excellent) Study Rundown: This study examined whether treatment with the combination of lenvatinib plus pembrolizumab provided greater benefits…
Source: 2 Minute MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
Previously treated advanced #endometrialcancer treated with #lenvatinib plus #pembrolizumab results in greater survival than #chemotherapy alone. Update From #KEYNOTE-775 #Clinicaltrial. From @JCO_ASCO via @2minmed #gyncsm @Lenvima_HCP @KEYTRUDA https://t.co/iUl2T60bBW
-
-
Mashup Score: 2
Expert panelists provide their perspective on the real-world use of combination lenvatinib + pembrolizumab in patients with MMRp recurrent endometrial carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Expert panelists provide their perspective on the real-world use of combination #lenvatinib + #pembrolizumab in patients with MMRp recurrent endometrial carcinoma. #gyncsm | @TexasOncology @uamshealth https://t.co/s7QxwLKG8M
-
-
Mashup Score: 0
New data assessed the OS and PFS of lenvatinib plus pembrolizumab and sunitinib alone based on a 7-month extended follow-up analysis of the CLEAR trial.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Which #aRCC treatment is the most effective: #lenvatinib + pembrolizumab, or #sunitinib alone? A 7-month follow-up study of the phase 3 CLEAR trial evaluated the progression-free survival and overall survival rates of both treatments. Learn more: https://t.co/v6dxz95mDB https://t.co/Gy9KviDdEA
-
-
Mashup Score: 4
Neither the LEAP-003 nor LEAP-017 studies study showed survival benefit with pembrolizumab plus lenvatinib for patients with melanoma or colorectal cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the phase 3 LEAP-003 and LEAP-017 trials, the primary end point of overall survival failed to be met when patients with #melanoma or #colorectalcancer were administered the combination of #pembrolizumab and #lenvatinib. #melsm #crcsm | @Merck https://t.co/rMMljtoT3E
-
A recent study has concluded that #lenvatinib after immunotherapy progression can be beneficial as a second-line therapy for patients with hepatocellular carcinoma. Read more: https://t.co/dVTINT0DoQ https://t.co/PLXxo1v3FS